about
β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastomaAzaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivoThe bone marrow microenvironment in Waldenström macroglobulinemiaVery late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myelomaToll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosisFunctional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML)Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin.CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myelomaCXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma.The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas.Tumor-targeting peptides from combinatorial libraries.Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.Reelin promotes the adhesion and drug resistance of multiple myeloma cells via integrin β1 signaling and STAT3.Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins.Highly Expressed Integrin-α8 Induces Epithelial to Mesenchymal Transition-Like Features in Multiple Myeloma with Early Relapse.Cancer-stromal interactions: role in cell survival, metabolism and drug sensitivity.Novel treatment options for Waldenström macroglobulinemiaRANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines.Creating artificial lymphoid tissues to study immunity and hematological malignancies.Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferationTumor cell migration and invasion are regulated by expression of variant integrin glycoformsHSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma.Outcomes of primary refractory multiple myeloma and the impact of novel therapies.Stimulation of Toll-like receptor-1/2 combined with Velcade increases cytotoxicity to human multiple myeloma cells.Cell Trafficking in Multiple MyelomaAggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cellsRole of stromal cell-mediated Notch signaling in CLL resistance to chemotherapy.
P2860
Q24564890-09B22712-40B3-46D2-A73B-892C128A6E65Q24670297-E2815D67-E3BE-49EE-9C5E-7F319231D6A9Q27028214-D3A3DF2A-FDB4-4F85-B637-C38F39C64DE9Q27316139-62B72A4A-7E94-499A-ADF5-917EB2403512Q28538422-03DD0259-C391-4896-A5E2-763C3FF004E8Q28546856-792E5653-40C5-4ECF-8CB0-F0E0EA383168Q30408322-6B5163BE-1053-415E-AA3C-AA5F5151C338Q30487339-FE8E916A-0BB5-473B-A90B-A53101B42D38Q33749646-413F54D6-B0F4-4B3C-9461-A6181C6BE4B7Q34209313-4799545C-5627-40B3-9501-A51D544AF82AQ35773205-81C42C5B-9AA2-4BBC-A405-B044EC23B298Q35989467-54FC8F6B-8D11-46E5-B896-71713CB9E66BQ36025723-79CAB568-FD38-42AA-ADC5-BBEA90C34EC5Q36217436-4E951DF6-050E-4B92-9DA9-7622CE939361Q36962815-64E3BBAD-AF0E-4F95-B647-781095A2B56DQ37499263-3A0B2F78-F619-4BA3-8465-A609C855E969Q37575786-7A16B69F-46CC-408B-9A72-B67035777EB3Q37824564-A2C33AD6-862A-4B99-B3FE-77A76AA2EC29Q38167433-A5571536-068B-4F92-85A0-B26D1BE98B36Q38804090-F3964428-037D-4835-AA1B-7CA95044CCE0Q39252350-3003D03A-A994-4365-9ADE-4C205ECE5827Q39893169-59F85BF9-608A-4BBA-917C-0987B420964BQ39950698-E72386BD-7383-4641-9B83-64E370998193Q39978610-0E4FE83C-7435-44F5-8658-3805876B1784Q41543966-958B7040-2BEA-42FD-9DCB-D5A0F6408279Q41876189-3D47436D-3076-4111-88DF-BA350533CAF0Q42146660-77C9BA67-0244-43F3-B417-DA2049BE565CQ42156460-E6658205-F1B7-49EC-B3A3-212EE846EB49Q42183094-FDC360E6-4495-4413-B797-297011927C55
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Integrin-mediated drug resistance in multiple myeloma.
@ast
Integrin-mediated drug resistance in multiple myeloma.
@en
type
label
Integrin-mediated drug resistance in multiple myeloma.
@ast
Integrin-mediated drug resistance in multiple myeloma.
@en
prefLabel
Integrin-mediated drug resistance in multiple myeloma.
@ast
Integrin-mediated drug resistance in multiple myeloma.
@en
P1433
P1476
Integrin-mediated drug resistance in multiple myeloma.
@en
P2093
P356
10.3109/10428190009060320
P577
2000-06-01T00:00:00Z